Circulating levels of plasminogen activator inhibitor-1 are associated with metabolic syndrome rather than with menopause

References

• Córdova-Pérez N, Basurto Acevedo L, Degollado Córdova J, et al. Menopausal women have hypofibrinolysis even in subclinical stage of atherosclerosis. Rev Invest Clin. 2015;67:122–129.
   PubMedGoogle Scholar
• Smith LH, Coats SR, Qin H, et al. Differential and opposing regulation of PAI-1 promoter activity by estrogen receptor alpha and estrogen receptor beta in endothelial cells. Circulation Res. 2004;95:269–275.
   PubMed Web of Science ®Google Scholar
• Aso Y. Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci. 2007;12:2957–2966.
   PubMed Web of Science ®Google Scholar
• Al Hamodi Z, Ismail I, Saif Ali R, et al. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in malaysian subjects. Cardiovasc Diabetol. 2011;10:23.
   PubMed Web of Science ®Google Scholar
• Takeshita K, Saito H, Yamamoto K. Plasminogen activator inhibitor-1 in aging. Semin Thromb Hemost. 2014;40:652–659.
   PubMed Web of Science ®Google Scholar
• Aburto-Mejía E, Santiago-Germán D, Martínez-Marino M, et al. Hypofibrinolytic state in subjects with type 2 diabetes mellitus aggravated by the metabolic syndrome before clinical manifestations of atherothrombotic disease. Biomed Res Int. 2017;2017:6519704.
   PubMed Web of Science ®Google Scholar
• Saucedo R, Basurto L, Zarate A, et al. Effect of estrogen therapy on insulin resistance and plasminogen activator inhibitor type 1 concentrations in postmenopausal women. Gynecol Obstet Invest. 2007;64:61–64.
   PubMed Web of Science ®Google Scholar
• Carr M. The Emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88:2404–2411.
   PubMed Web of Science ®Google Scholar
• Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med. 2016;26:364.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–1645.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and cell function from fasting plasma glucose and insulin concentrations in man. Diabet. 1985;28:412–419.
   Google Scholar
• Basurto L, Saucedo R, Zárate A, et al. Effect of pulsed estrogen therapy on hemostatic markers in comparison with oral estrogen regimen in postmenopausal women. Gynecol Obstet Invest. 2006;61:61–64.
   PubMed Web of Science ®Google Scholar
• Eriksson P, Van Harmelen V, Hoffstedt J, et al. Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals. Thromb Haemost. 2000;83:(4):545–548.
   Web of Science ®Google Scholar
• Pallottini V, Bulzomi P, Galluzzo P, et al. Estrogen regulation of adipose tissue functions: involvement of estrogen receptor isoforms. IDDT. 2008;8:52–60.
   Google Scholar
• Pedersen S, Kristensen K, Hermann P, et al. Estrogen controls lipolysis by up-regulating α2a-adrenergic receptors directly in human adipose tissue through the estrogen receptor α. Implications for the female fat distribution. J Clin Endocrinol Metab. 2004;89:1869–1878.
   PubMed Web of Science ®Google Scholar
• Kitamura H, Kimura S, Shimamoto Y, et al. Ubiquitin-specific protease 2-69 in macrophages potentially modulates inflammation. Faseb J. 2013;27:4940–4953.
   PubMed Web of Science ®Google Scholar
• Bastelica D, Mavri A, Verdier M, et al. Relationships between fibrinolytic and inflammatory parameters in human adipose tissue: strong contribution of TNF alpha receptors to PAI-1 levels. Thromb Haemost. 2002;88:481–487.
   PubMed Web of Science ®Google Scholar
• Eriksson P, Reynisdottir S, Lönnqvist F, et al. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Fibrinolysis and Proteolysis. 1997;41:28.
   Google Scholar
• Cigolini M, Targher G, Bergamo Andreis IA, et al. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol. 1996;16:368–374.
   PubMed Web of Science ®Google Scholar
• Zorio E, Gilabert EJ, Espana F, et al. Fibrinolysis: the key to new pathogenetic mechanisms. Curr Med Chem. 2008;15:923–929.
   PubMed Web of Science ®Google Scholar
• Barnard SA, Pieters M, De Lange Z. The contribution of different adipose tissue depots to plasma plasminogen activator inhibitor-1 (PAI-1) levels. Blood Rev. 2016;30:421–429.
   PubMed Web of Science ®Google Scholar
• El Khoudary SR, Shields KJ, Chen HY, et al. Menopause, complement, and hemostatic markers in women at midlife: the Study of Women’s Health Across the Nation. Atherosclerosis. 2013;231:54–58.
   PubMed Web of Science ®Google Scholar
• Barnard SA, Pieters M, Nienaber-Rousseau C, et al. Degree of obesity influences the relationship of PAI-1 with body fat distribution and metabolic variables in African women. Thromb Res. 2016;146:95–102.
   PubMed Web of Science ®Google Scholar
• Sowers MF, Randolph JF, Zheng H, et al. Genetic polymorphisms and obesity influence estradiol decline during the menopause. Clin Endocrinol (Oxf). 2011;74:618–623.
   PubMed Web of Science ®Google Scholar
• Kodaman N, Aldrich M, Sobota R, et al. Plasminogen activator inhibitor‐1 and diagnosis of the metabolic syndrome in a West African population. J Am Heart Assoc. 2016;5:e003867.
   PubMed Web of Science ®Google Scholar